• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Flow Sciences Appoints Michael Gesser as Chief Financial Officer

    4/8/26 8:00:00 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACOR alert in real time by email

    Life Sciences Finance Veteran and Flow Sciences Board Member Steps Into CFO Role to Support Company's Next Phase of Growth

    RALEIGH, N.C, April 8, 2026 /PRNewswire/ -- Flow Sciences, Inc., a global leader in advanced containment solutions for laboratory and pharmaceutical environments, today announced the appointment of Michael Gesser as its chief financial officer. Gesser, who has served as a member of the Flow Sciences board of directors since 2021, will continue serving on the board while assuming executive responsibility for all finance, accounting, tax, treasury, FP&A and investor relations functions.

    Michael Gesser, CFO

    Gesser brings more than 30 years of financial leadership experience across both publicly-traded and privately-held companies in the life sciences, pharmaceutical, and medical device sectors. His career includes CFO tenures at Acorda Therapeutics, Inc. (NASDAQ:ACOR), Osmotica Pharmaceutical, Tergus Pharma, BioMedomics, and SunTech Medical. He holds a B.S. from the Cameron School of Business at the University of North Carolina Wilmington and an MBA from the Belk College of Business at UNC Charlotte.

    As a Flow Sciences board member, Gesser played an integral role in the company's strategic expansion into the Research Triangle Park (RTP) area of North Carolina, one of the nation's leading hubs for biopharmaceutical research, innovation, and manufacturing. The RTP office, which opened in 2025, features a state-of-the-art product showroom, training facilities, and a consultative design center, strengthening Flow Sciences' presence in a region with deep concentrations of pharmaceutical and biotechnology clients.

    "Michael's appointment as CFO is a natural evolution of his already-significant contributions to Flow Sciences," said Jonathan Mann, Chief Executive Officer. "His deep financial expertise, his experience navigating both public and private company environments, and his long-standing familiarity with our business and strategy make him ideally suited to lead our financial function as we continue to grow. We're thrilled to have him step into this role."

    In his new capacity, Gesser will partner closely with Mann and the broader executive team to oversee financial strategy, capital structure management, budgeting, forecasting and compliance. He will also support the company's ongoing growth initiatives, including expansion of its containment solutions portfolio and continued investment in the RTP area presence.

    "I have had a front-row seat to Flow Sciences' evolution—the strength of its technology, the quality of its team, and the depth of its customer relationships," said Gesser. "I am honored to take on a more active role in driving the financial strategy that will support our next chapter. There is a tremendous opportunity ahead of us, and I look forward to helping the company capitalize on it."

    About Flow Sciences

    Flow Sciences delivers advanced containment solutions that help laboratories, manufacturers, and research organizations safely handle hazardous powders, fluids, and gases. With more than 30 years of expertise, the company engineers award-winning enclosures—such as the Vented Balance Safety Enclosure (VBSE™)—that meet rigorous safety regulations while optimizing workflow efficiency and minimizing downtime. Its modular, customizable systems are trusted worldwide across multiple industries. Flow Sciences provides expert engineering support for tailored containment solutions, guiding clients from design through installation, and offers comprehensive post-sales service to ensure ongoing performance and compliance. Backed by ISO 9001:2015 certification and proven performance data, Flow Sciences empowers organizations to protect personnel and products, simplify compliance, and maximize long-term value. For more information, visit flowsciences.com.

    Flow Sciences, Inc. (PRNewsfoto/Flow Sciences Inc)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/flow-sciences-appoints-michael-gesser-as-chief-financial-officer-302736093.html

    SOURCE Flow Sciences Inc

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Acorda Therapeutics upgraded by HC Wainwright & Co. with a new price target

    HC Wainwright & Co. upgraded Acorda Therapeutics from Neutral to Buy and set a new price target of $10.00 from $5.00 previously

    6/17/21 6:09:07 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Flow Sciences Appoints Michael Gesser as Chief Financial Officer

    Life Sciences Finance Veteran and Flow Sciences Board Member Steps Into CFO Role to Support Company's Next Phase of GrowthRALEIGH, N.C, April 8, 2026 /PRNewswire/ -- Flow Sciences, Inc., a global leader in advanced containment solutions for laboratory and pharmaceutical environments, today announced the appointment of Michael Gesser as its chief financial officer. Gesser, who has served as a member of the Flow Sciences board of directors since 2021, will continue serving on the board while assuming executive responsibility for all finance, accounting, tax, treasury, FP&A and investor relations functions.

    4/8/26 8:00:00 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acorda Therapeutics Announces Delisting from Nasdaq

    Acorda Therapeutics, Inc. today announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the Company's commencement of Chapter 11 proceedings and Nasdaq Listing Rule 5450(b)(1)(A) for failure to maintain stockholders' equity of at least $10 million. Trading in the Company's common stock on the Nasdaq exchange was suspended on April 12, 2024. The Company's common stock is quoted on the OTC Pink® Open Market platform operated by OTC Markets Group Inc. since April 12, 2024 under the "ACORQ" ticker symbol. About Acorda Therap

    4/15/24 5:03:00 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acorda Therapeutics Announces Nasdaq Delisting Notification

    Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of business on April 12, 2024. The notice follows the Company's April 1, 2024 announcement that it has reached an agreement with Merz Therapeutics to acquire substantially all of the assets of the Company. In connection with that announcement, Acorda and certain of its affiliates filed voluntary petitions to commence Chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of New York. Nasdaq commenced proceedings to delist the Company's common stock, based on th

    4/3/24 5:30:00 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Burns Thomas M.

    4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

    6/23/23 7:59:21 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Burns Thomas M.

    3 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

    6/23/23 7:57:11 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Varian John

    4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

    6/23/23 5:38:37 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    SEC Filings

    View All

    SEC Form 10-Q filed by Acorda Therapeutics Inc.

    10-Q - Acorda Therapeutics, Inc. (0001008848) (Filer)

    5/14/24 8:24:14 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K/A filed by Acorda Therapeutics Inc. (Amendment)

    10-K/A - Acorda Therapeutics, Inc. (0001008848) (Filer)

    4/29/24 8:39:11 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acorda Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Acorda Therapeutics, Inc. (0001008848) (Filer)

    4/25/24 8:00:48 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    Leadership Updates

    Live Leadership Updates

    View All

    Flow Sciences Appoints Michael Gesser as Chief Financial Officer

    Life Sciences Finance Veteran and Flow Sciences Board Member Steps Into CFO Role to Support Company's Next Phase of GrowthRALEIGH, N.C, April 8, 2026 /PRNewswire/ -- Flow Sciences, Inc., a global leader in advanced containment solutions for laboratory and pharmaceutical environments, today announced the appointment of Michael Gesser as its chief financial officer. Gesser, who has served as a member of the Flow Sciences board of directors since 2021, will continue serving on the board while assuming executive responsibility for all finance, accounting, tax, treasury, FP&A and investor relations functions.

    4/8/26 8:00:00 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acorda Therapeutics Announces Resignation of Chief Operating Officer

    Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. "We are grateful for Lauren's thirteen years of contributions as a member of Acorda's executive leadership team. Initially, she and her team led the commercial launch of AMPYRA, a novel treatment for multiple sclerosis. The tremendous success of that product allowed Acorda to invest in additional clinical development programs, including INBRIJA for Parkinson's disease," said Ron Cohen, M.D., Acorda's President and CEO. "Lauren has been

    8/19/22 8:00:00 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    Financials

    Live finance-specific insights

    View All

    Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024

    Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET. The Company does expect to timely file its Annual Report on Form 10-K for the period ended December 31, 2023. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor

    4/1/24 4:01:00 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024

    Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET. To participate in the webcast, please use the following registration link: https://events.q4inc.com/attendee/373031481 If you register for the webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the webcast details. On the day of the webcast, you will receive an email 2 hours prior to the start of the webcast with the link to join. The presentation will be

    3/25/24 4:01:00 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acorda Therapeutics Reports Third Quarter 2023 Financial Results

    INBRIJA® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4% increase over Q3 2022 AMPYRA® (dalfampridine) Q3 2023 net revenue of $15.7 million; 26% decrease over Q3 2022 INBRIJA ex-U.S. revenue of $1.4 million; FAMPYRA royalties of $2.5 million Biopas Laboratories files for approval of INBRIJA in six Latin American countries Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2023. "We were pleased to see a 32% increase in new INBRIJA prescription requests in Q3 2023 over Q3 2022. New prescription requests have increased by 38% in the first three quarters o

    11/13/23 4:01:00 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Acorda Therapeutics Inc. (Amendment)

    SC 13D/A - Acorda Therapeutics, Inc. (0001008848) (Subject)

    5/10/23 4:37:39 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Acorda Therapeutics Inc. (Amendment)

    SC 13D/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)

    3/10/23 4:15:17 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Acorda Therapeutics Inc. (Amendment)

    SC 13G/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)

    2/14/23 4:52:06 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care